---
schema_version: "secwatch.filing_event.v1"
accession: "0001575872-23-000023"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:49:22.143091+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TradeUP Acquisition Corp. extends business combination deadline to July 19, 2023; 3.52M shares redeemed

## Summary
- Stockholders approved extension of deadline from Jan 19, 2023 to July 19, 2023 at special meeting on Dec 22, 2022.
- On Dec 29, 2022, company filed charter amendment and entered into trust agreement amendment to effect the extension.
- In connection with extension vote, 3,519,780 shares of common stock were redeemed.
- Trust account holds $45,186,000 from offering and private placement.

## SEC filing metadata
- accession: 0001575872-23-000023
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000157587223000023/0001575872-23-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000157587223000023/uptd-20221229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001575872-23-000023
- JSON: https://secwatch.observer/filing/0001575872-23-000023.json
- Plain text: https://secwatch.observer/filing/0001575872-23-000023.txt

## Key facts
- Governance Changes
  Estrella Immunopharma, Inc.: Amended certificate of incorporation to extend the date for completing a business combination from January 19, 2023 to July 19, 2023 (effective 2022-12-29).
  - Change: charter amendment
  - Effective: 2022-12-29
  source text: At the Special Meeting, the stockholders of the Company also approved the proposal to amend the Company’s amended and restated certificate of incorporation (the “Charter”) to extend the date before which the Company must complete a business combination from January 19, 2023 to July 19, 2023 or such earlier date as determined by the board of directors of the Company (such extension is herein referred to as the “Extension”), and provide that the date for cessation of operations of the Company if the Company has not completed a business combination would similarly be extended (the “Extension Proposal”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000157587223000023/0001575872-23-000023-index.htm
- Material Agreements
  Estrella Immunopharma, Inc. amended Amendment to Investment Management Trust Agreement with Wilmington Trust, National Association (effective 2022-12-29).
  - Action: amendment
  - Counterparty: Wilmington Trust, National Association
  - Effective: 2022-12-29
  source text: a special meeting of stockholders (the “Special Meeting”), where the stockholders of the Company approved the Company to, among others, amend the Investment Management Trust Agreement dated July 14, 2021 (the “Trust Agreement”), by and between the Company and Wilmington Trust, National Association (the “Trustee”) to extend the liquidation date from January 19, 2023 to July 19, 2023 .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000157587223000023/0001575872-23-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.